Gargi Upadhyaya
Medical Oncology · Pasadena, CANPI 1013957190
Payments from drug & device makers
Across 90 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$369
- Incyte Corporation$279
- Astellas Pharma US Inc$260
- Novartis$184
- Pfizer$127
- E.r. Squibb & Sons, L.L.C.$127
- plus $836 from 22 others
What the payments were for
- Food & beverage$1,77481%
- Education$40619%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $369 |
| Incyte Corporation | 7 | $279 |
| Astellas Pharma US Inc | 5 | $260 |
| Novartis | 11 | $184 |
| Pfizer | 7 | $127 |
| E.r. Squibb & Sons, L.L.C. | 7 | $127 |
| Puma Biotechnology, Inc. | 3 | $72 |
| Gilead | 2 | $68 |
| Bayer | 3 | $67 |
| Exelixis Inc. | 3 | $66 |
| Merck | 3 | $51 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $50 |
| AbbVie | 1 | $47 |
| Amgen | 2 | $45 |
| Johnson & Johnson | 3 | $44 |
| Karyopharm Therapeutics Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Sanofi | 2 | $35 |
| Taiho Oncology, Inc. | 1 | $25 |
| Alk-abello, Inc | 1 | $25 |
| Clovis Oncology, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Seagen Inc. | 1 | $22 |
| Global Blood Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Boston Scientific | 1 | $11 |
How this compares
$2,180 in reported general payments places this provider in the 25th percentile of 379 medical oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpdualagNivolumab-Relatlimab-Rmbw | 13 | $383,833 |
| NubeqaDarolutamide | 19 | $326,684 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $231,743 |
| RevlimidLenalidomide | 19 | $227,408 |
| OpdivoNivolumab | 24 | $219,016 |
| YervoyIpilimumab | 12 | $200,479 |
| Lupron DepotLeuprolide Acetate | 72 | $187,698 |
| Lenalidomide | 13 | $175,543 |
| KeytrudaPembrolizumab | 16 | $167,416 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 13 | $160,767 |
| HerceptinTrastuzumab | 23 | $99,075 |
| ProcritEpoetin Alfa | 60 | $79,500 |
| RituxanRituximab | 24 | $79,332 |
| EliquisApixaban | 42 | $28,266 |
| MounjaroTirzepatide | 13 | $13,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Opdualag, Opdivo, Yervoy | $127 | $803,32749 claims |
| BayerNubeqa | $67 | $326,68419 claims |
| Bristol Myers SquibbRevlimid | $22 | $227,40819 claims |
| AbbVieLupron Depot | $47 | $187,69872 claims |
| MerckKeytruda | $51 | $167,41616 claims |
| NovartisSandostatin Lar Depot | $184 | $160,76713 claims |
| Johnson & JohnsonProcrit | $44 | $79,50060 claims |
| PfizerEliquis | $127 | $28,26642 claims |
| AstraZenecaBrilinta | $369 | $5,89013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 379 medical oncology providers in California.
Other medical oncology in Pasadena
- Yuan YuanPasadena$9.5M
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.